Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Leukotriene receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Leukotriene receptor. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-000715-71 Sponsor Protocol Number: CADET-PAD Start Date*: 2021-07-18
    Sponsor Name:Jagiellonian University Medical College
    Full Title: The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatm...
    Medical condition: Occlusive atherosclerosis in patients treated endovascularly due to ischemia of the lower limbs in the course of obstructive artery disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10067825 Peripheral arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003061-25 Sponsor Protocol Number: MPEEG_2 Start Date*: 2016-12-14
    Sponsor Name:Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University Salzburg
    Full Title: Pharmaco-EEG for Montelukast. Can we detect neural changes during medication with Montelukast in the EEG?
    Medical condition: Montelukast is indicated for prophylaxis and chronic treatment of asthma and for the relief of symptoms of seasonal allergic rhinitis. We investigate side effects of Montelukast, specifically poten...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001008-21 Sponsor Protocol Number: 2014/07 Start Date*: 2008-01-20
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Effect of leukotriene gene polymorphisms on response to montelukast, a leukotriene receptor antagonist, in adults with asthma
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002154-36 Sponsor Protocol Number: CIGE025F1301 Start Date*: 2019-02-13
    Sponsor Name:Novartis Pharma KK
    Full Title: A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled...
    Medical condition: Severe Japanese cedar pollinosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036020 Pollinosis LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022784-35 Sponsor Protocol Number: Q4883g Start Date*: 2011-08-08
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE TREATME...
    Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021247 Idiopathic urticaria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000543-27 Sponsor Protocol Number: 19852012 Start Date*: 2012-04-23
    Sponsor Name:AMC
    Full Title: A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-Liposomal Prednisolone Sodium Phosphate (Nanocort®) in Atherosclerotic Tissue in Subjects with Pe...
    Medical condition: Vessel wall inflammation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003663-35 Sponsor Protocol Number: PBF-680CT-05 Start Date*: 2018-06-13
    Sponsor Name:Palobiofarma S.L
    Full Title: A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1...
    Medical condition: patients with mild-to-moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000164-42 Sponsor Protocol Number: 2016RC01 Start Date*: 2016-08-17
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee
    Full Title: JAB02 Repurposing allopurinol as a novel anti-inflammatory treatment for persistent allergic asthma.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003609-24 Sponsor Protocol Number: CLOU064D12201 Start Date*: 2019-10-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma
    Medical condition: Inadequately controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000511-16 Sponsor Protocol Number: HTA05/503/04 Start Date*: 2008-08-22
    Sponsor Name:Keele University [...]
    1. Keele University
    2. University Hospital of North Staffordshire NHS Trust
    Full Title: Management of Asthma in School age Children On Therapy
    Medical condition: Chronic asthma (paediatric population)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    9.1 10049868 Asthma exacerbation prophylaxis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001644-29 Sponsor Protocol Number: SAS115359 Start Date*: 2012-05-04
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed) LT (Completed) SE (Completed) LV (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed) SK (Completed) FI (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-002669-16 Sponsor Protocol Number: GA43512 Start Date*: 2022-04-04
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF MTPS9579A IN PARTICIPANTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA
    Medical condition: Refractory Chronic Spontaneous Urticaria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005084-32 Sponsor Protocol Number: D6230C00001 Start Date*: 2015-06-05
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018315-15 Sponsor Protocol Number: D589GC00001 Start Date*: 2010-06-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo, a 6-week efficacy and safety study in children aged 6 ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LV (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003612-28 Sponsor Protocol Number: 206785 Start Date*: 2021-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomised, double-blind, double-dummy, parallel group,multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and ad...
    Medical condition: Severe asthma with an eosinophilic phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) SI (Trial now transitioned) NO (Trial now transitioned) PL (Completed) FI (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000460-42 Sponsor Protocol Number: AK001-002 Start Date*: 2016-06-29
    Sponsor Name:Allakos, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis
    Medical condition: Moderate to severe nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001217-20 Sponsor Protocol Number: LPS16677 Start Date*: 2020-09-11
    Sponsor Name:Sanofi Aventis Recherche & Developpement
    Full Title: A phase 4, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the effect of dupilumab on sleep disturbance in patients with uncontrolled persistent asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002142-13 Sponsor Protocol Number: P06241/P202 Start Date*: 2012-05-30
    Sponsor Name:Merck Sharp & Dohme Corp
    Full Title: A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) CZ (Completed) LV (Completed) GB (Completed) ES (Completed) DE (Completed) IE (Completed) SK (Completed) PL (Completed) IT (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001273-16 Sponsor Protocol Number: CQAW039A2316 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled as...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001573-40 Sponsor Protocol Number: EFC13691 Start Date*: 2015-11-04
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Severe Steroid Dependent Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:51:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA